Latest Breaking News On - Primary endpoint - Page 7 : comparemela.com

Why Aldeyra Therapeutics Stock Is Trading Higher Today

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica

Aldeyra therapeutics incAldeyra highlightsNew drug applicationBenzinga proAllergic conjunctivitisPrimary endpointStatistical significanceAldeyra therapeuticsOphthalmic solution

First-Line or Second Fiddle? Conduction System Pacing in HF

Resynchronization therapy jumps forward with 3 new studies that support but push the envelope of a new guideline statement on physiologic pacing for heart failure.

United statesNorth carolinaDuke university medical centerJuanc diazSanam al khatibColl cardiolZachary goldbergerJorge romero jrNiraj varmaYong mei chaLas vegasPugazhendhi vijayaramanGeisinger heart instituteJournal of the american college cardiologyUniversity of wisconsin school medicineHeart rhythm society

Radio Apocalypse: Hardening AM Radio Against Disasters

Radio Apocalypse: Hardening AM Radio Against Disasters
hackaday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hackaday.com Daily Mail and Mail on Sunday newspapers.

United statesEmergency management agencyCommunication commissionMount weather emergency operations centerFederal communication commissionCold warEmergency alert systemSpecific area message encodingIntegrated public alertWarning systemPrimary endpointPrimary entry pointFederal emergency management agencyMount weatherCarrington event levelNew orleans

NewAmsterdam Pharma Company B V : NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate

United statesNoord hollandHannah deresiewiczChristiem ballantyneMatthew philippeCompany phaseExchange commissionCompany contactCardiovascular researchFrazier lifesciences acquisition corporationNational lipid associationNeither the companyNewamsterdam pharma companynv nasdaqBaylor college of medicineMenarini groupPrimary endpoint

BioXcel Therapeutics (BTAI) Announces Promising Topline Results from Part 1 of SERENITY III Trial of BXCL501

BioXcel Therapeutics (BTAI) Announces Promising Topline Results from Part 1 of SERENITY III Trial of BXCL501
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesScott stachowiakrussoRobert risingerJohn krystalCorporatebioxcel therapeuticserik koppVimal mehtaRobertl mcneil jrRelationsbioxcel therapeuticsbrennan doyleSecurities exchangeBioxcel therapeutics incNational institute of mental healthWhile the companyProfessor of translational researchXcel therapeuticsTranslational researchYale school